Resistant Hypertension in Chronic Kidney Disease
209 Additionally, recent meta-analyses have provided further support for the therapeutic benefit of CPAP therapy specifically on ...
210 Although CPAP can be expected to achieve a lesser magnitude of blood pressure reduction than antihypertensive medications, t ...
211 Effect of MADs on Blood Pressure A few studies have demonstrated a favorable effect of MADS on blood pressure reduction in p ...
212 Self-reported compliance with MAD was greater than the objectively measured one with CPAP therapy, raising the possibility t ...
213 Conclusions A large body of evidence supports the role of OSA as an independent factor in the pathogenesis of daytime hypert ...
214 Cano-Pumarega I, Durán-Cantolla J, Aizpuru F, Miranda-Serrano E, Rubio R, Martínez-Null C, et al. Obstructive sleep apnea a ...
215 Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LKG, Amaro ACS, et al. Obstructive sleep apnea: the most common secon ...
216 Epstein LJ, Kristo D, Strollo PJ, Friedman N, Malhotra A, Patil SP, et al. Clinical guideline for the evaluation, managemen ...
217 sion and obstructive sleep apnea: a meta-analysis. J Hypertens. 2014;32(12):2341–50; discus- sion 2350. Pépin J-L, Tamisier ...
218 Sutherland K, Vanderveken OM, Tsuda H, Marklund M, Gagnadoux F, Kushida CA, et al. Oral appliance treatment for obstructive ...
© Springer International Publishing AG 2017 219 A. Covic et al. (eds.), Resistant Hypertension in Chronic Kidney Disease, DOI 10 ...
220 The approach to treatment of resistant hypertension in patients with chronic kid- ney disease (CKD) should target several fa ...
221 prospectively enrolled to compare high and low-sodium diet according to antihyper- tensive and antiproteinuric effects of AR ...
222 (force-titrated to 25 mg/day) and HCTZ 25 mg/day (force-titrated to 50 mg/day) on ABPM in untreated hypertensive patients af ...
223 and an eGFR 50–60 mL/min, but it doubles the risk of hyperkalemia when added to ACEi or ARB in patients with moderate chroni ...
224 Deal with Enhanced Sympathetic Activation: Beta-Blockers The sympathetic nervous system is activated in CKD which acts an im ...
225 (11.3 mmHg) after 6 weeks of treatment. Later studies have focused on the impact of ERAs in the setting of resistant hyperte ...
226 Deal with Non-dipping Status: Chronotherapy The non-dipping pattern refers the situation of impaired circadian BP rhythm, an ...
227 morning to evening (maintaining the same drugs at the same doses) improves ABPM control after 6 weeks. At the end of the stu ...
228 decrease in mean sleep-time systolic BP was related with a 14% reduction in the risk for cardiovascular events during follow ...
«
7
8
9
10
11
12
13
14
15
16
»
Free download pdf